Synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as possible anticancer agents
ACTA PHARMACEUTICA, vol.70, no.4, pp.499-513, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 70 Issue: 4
- Publication Date: 2020
- Doi Number: 10.2478/acph-2020-0034
- Journal Name: ACTA PHARMACEUTICA
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
- Page Numbers: pp.499-513
- Keywords: 1,3,4-thiadiazole, anticancer activity, aromatase inhibitory activity, MTT assay, INHIBITORY-ACTIVITY, AMINOGLUTETHIMIDE, HETEROCYCLES, BINDING
- Open Archive Collection: AVESIS Open Access Collection
- Anadolu University Affiliated: Yes
Abstract
The synthesis of new N-(5-substituted-1,3,4-thiadiazol-2-yl)-2-[5-(substituted amino)-1,3,4-thiadiazol-2-yl)thiolacetamide derivatives and investigation of their anticancer activities were the aims of this work. All the new compounds' structures were elucidated by elemental analyses, IR, H-1 NMR, C-13 NMR and MS spectral data. Anticancer activity studies of the compounds were evaluated against MCF-7 and A549 tumor cell lines. In addition, with the purpose of determining the selectivity of cytotoxic activities, the most active compound was screened against a noncancer NIH3T3 cell line (mouse embryonic fibroblast cells). Among the tested compounds, compound 4y (N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-((5-(p-tolylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide), showed promising cytotoxic activity against MCF7 cancer cell with an IC50 value of 0.084 +/- 0.020 mmol L-1, and against A549 cancer cell with IC50 value of 0.034 +/- 0.008 mmol L compared with cisplatin. The aromatase inhibitory activity was evaluated for compound 4y on MCF-7 cell line showing promising activity with IC50 of 0.062 +/- 0.004 mmol L-1.